Your session is about to expire
← Back to Search
EAAT2 PET Tracer for Dementia
Study Summary
This trial will assess a new agent that may be able to detect Alzheimer's disease earlier than current methods.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I do not have any visible physical disorders.My arm's main arteries are suitable for a catheter procedure.You cannot have a magnetic resonance imaging (MRI) scan because you have a pacemaker, implantable metallic device, or severe fear of enclosed spaces.I am between 40 and 75 years old.I haven't had certain types of scans that could interfere with new tests in the last few weeks.I am not pregnant.I have someone who knows about my daily activities and can talk about my mental and physical abilities.You do not have suitable arteries for the procedure.For Cohort 2 part B only: You have to have taken a mini mental examination within the past 6 months.I cannot or will not follow the study rules, or no one can consent for me.My BMI is appropriate for my age.You cannot have had more than 3 [18F]RP-115 scans in the past year.I do not smoke or use nicotine replacement therapies.I haven't taken any CNS prescription drugs for the last three weeks.
- Group 1: Cohort 2C - [18F]RP-115 in patients with FTD
- Group 2: Cohort 2B - [18F]RP-115 in patients with AD
- Group 3: Cohort 2A - [18F]RP-115 in age-matched controls
- Group 4: Cohort 1 - dosimetry of [18F]RP-115 in healthy volunteers
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical experiment open to elderly subjects?
"According to the trial's entrance requirements, minimum age for participation is 40 and maximum age is 75."
What is the aggregate number of participants involved in this trial?
"That is correct. Clinicaltrials.gov indicates that this medical research, which was initially shared on November 2nd 2021, has opened up registration to 68 people at a single location."
Do I meet the prerequisites to participate in this trial?
"With the purpose of studying Alzheimer's disease, this clinical trial is recruiting 68 participants aged between 40 and 75. Applicants must fulfil a selection of criteria such as: being within age parameters; having an appropriate Body Mass Index (BMI); providing written informed consent or possessing someone to grant surrogate approval on their behalf; lacking any physical ailments; presenting suitable radial, ulnar, or brachial arteries for catheterization purposes; not smoking nor consuming nicotine-based products over the counter, plus avoiding central nervous system medications three weeks prior to enrollment in order to limit peripheral metabolism events; procuring a support person that spends at least five hours"
Are there opportunities presently available to participate in this trial?
"According to clinicaltrials.gov, this research program is actively recruiting participants since its posting date of November 2nd 2021 and subsequent update on May 9th 2022."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger